Answers are grounded in this paper and cite their sources.
Colon cancer is the third most prevalent type of cancer worldwide. 5-Fluorouracil (5-FU), utilised in the treatment of colon cancer, exerts its function as an antimetabolite, thereby disrupting the DNA and RNA synthesis of cancer cells by means of the inhibition of thymidylate synthase. Although it has been used for a long time, side effects such as bone marrow suppression, skin reactions and gastrointestinal problems, as well as resistance mechanisms, still pose problems. In this study, the drug delivery system known as MIL-100 was modified with pectin and encapsulated with 5-FU to promote controlled release in the target area. The present study has successfully demonstrated the modification of pectin and the loading of drug by means of FT-IR, TGA and zeta potential studies. In dissolution media simulating gastric (pH 1.2 acetate buffer) and colonic (pH 7.4 phosphate buffer) environments, the 5-FU delivery system exhibited cumulative release values of 48.75 and 98.25 respectively. The drug release kinetics were best described by the Korsmeyer–Peppas model. The calculated release exponent (n) values (0.345 at pH 1.2 and 0.569 at pH 7.4) indicated a transition from Fickian diffusion to non-Fickian transport, highlighting the pH-responsive degradation of the carrier system. Overall, these findings demonstrate that the engineered carrier system represents a promising platform for colon-specific drug delivery, offering controlled release characteristics tailored to the physiological gradients of the gastrointestinal tract.
No takes yet. Share an insight, caveat, or question.
Özsoy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: